Here, we report the use of in-depth immunophenotyping of MS patients and controls to investigate the association of PD-1/PD-L1 with clinical disease measures in MS and to evaluate the potential of the PD-1/PD-L1 axis as a potential target for therapeutic modulation during acute CNS inflammation. Here, PDCD1 is linked to myeloid sarcoma.